JNJ

As of 2026-09-11, JNJ scores 54out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. JNJ trades at $265.58, 8% above the band ceiling.

JNJ scores 54 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 54. Its strongest factor is value at 64 (solid), where it screens cheap on the model's valuation inputs, followed by sentiment at 62. The weakest is volume at 47, where volume gives little confirmation. Among Healthcare stocks it ranks in roughly the top 22% of the Healthcare names the model scores.

On valuation, JNJ is priced near the top of its recent range — the rich end on the model's valuation read. The five factors sit close together, so the composite reflects a balanced profile rather than one dominant driver. The blended composite before the macro overlay was 56. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on JNJ, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where JNJ sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for JNJ runs $196.51–$244.89. Current price $265.58 sits 8% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.